Current clinical studies on 5-ALA-FD (5-aminolevulinic acid mediated-fluorescence guided detection) in detection of lung, gastric, pancreatic, and bladder cancers in Japan (Conference Presentation)

Motowo Nakajima

doi:10.1117/12.2527963

14 August 2019 Current clinical studies on 5-ALA-FD (5-aminolevulinic acid mediated-fluorescence guided detection) in detection of lung, gastric, pancreatic, and bladder cancers in Japan (Conference Presentation)

Motowo Nakajima

Author Affiliations +

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 1107020 (2019) https://doi.org/10.1117/12.2527963
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

SBI Pharmaceuticals Co., Ltd. (SBI) is a pharmaceutical authorization holder of the orally available 5-aminolevulinic acid (5-ALA) in Japan for visualization of glioma and bladder cancer. SBI provides 5-ALA as a research material and makes mutual collaborations with academic institutions. We examined four published studies of 5-ALA-FD (5-ALA fluorescence guided detection) conducted in Japan. 5-ALA was orally administrated at 20mg/kg body weight or 1g per patient at 2-4 hours before surgery or diagnosis. Bladder cancer: The presence of CIS (carcinoma in situ) affects recurrence of non-muscle-invasive bladder cancer. Additional CISs were detected and diagnosed only by 5-ALA-FD in 9 out of 60 patients and they were classified as high risk group. Peritoneal metastasis of gastric cancer: The addition of 5-ALA-FD to conventional laparoscopy enabled us to identify usually invisible peritoneal metastases in 5 of 24 patients with advanced gastric cancer. Pancreatic cancer: Peritoneal nodules suspected to be peritoneal metastases were observed under white light in 9 of 34 patients. The nodules in 4 of 9 patients showed fluorescence by 5-ALA-FD and were histopathologically diagnosed as metastases. Lung cancer: Fluorescence was confirmed in 14 of 14 PL1-PL3 patients and 10 of 24 PL0 patients. PL0 patients showed red fluorescence were preoperatively diagnosed as stage PL1. Accurate intraoperative diagnosis for visceral pleural invasion in lung cancer was performed by 5-ALA-FD. Four studies indicate that 5-ALA-FD is useful for distinction of tumors such as small lesions and contributes to selection of an appropriate therapy without a non-curative resection.

Conference Presentation

Citation Download Citation

Motowo Nakajima "Current clinical studies on 5-ALA-FD (5-aminolevulinic acid mediated-fluorescence guided detection) in detection of lung, gastric, pancreatic, and bladder cancers in Japan (Conference Presentation)", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 1107020 (14 August 2019); https://doi.org/10.1117/12.2527963

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Bladder cancer

Luminescence

Lung

Cancer

Lung cancer

Copper indium disulfide

Fluorescence spectroscopy

Show All Keywords

Keywords/Phrases

Search In:

Publication Years